Core Viewpoint - Addex Therapeutics reported its Q1 2024 financial results, highlighting a focus on advancing drug candidates in collaboration with Indivior and other partners, while also addressing financial performance and operational changes following the Neurosterix transaction. Financial Summary - Income for Q1 2024 was CHF 235,000, down from CHF 502,000 in Q1 2023, a decrease of CHF 267,000 [5] - R&D expenses remained stable at CHF 245,000 in Q1 2024 compared to CHF 255,000 in Q1 2023, showing a slight decrease of CHF 10,000 [5] - G&A expenses increased to CHF 778,000 in Q1 2024 from CHF 615,000 in Q1 2023, an increase of CHF 163,000 primarily due to legal fees [5] - Total operating loss for Q1 2024 was CHF 788,000, compared to CHF 368,000 in Q1 2023, an increase of CHF 420,000 [5] - Net loss from continuing operations was CHF 735,000 in Q1 2024, up from CHF 370,000 in Q1 2023, an increase of CHF 365,000 [5] - Net loss for the period was CHF 3,087,000, compared to CHF 2,407,000 in Q1 2023, an increase of CHF 680,000 [5] Operational Highlights - The selection of drug candidates under the GABAB PAM collaboration with Indivior is expected by the end of Q2 2024 [2] - The company launched Neurosterix with Perceptive Advisors, raising USD 63 million in Series A funding to accelerate the development of a preclinical portfolio [5] - Addex received CHF 5 million and a 20% equity stake in Neurosterix in April 2024, extending its cash runway beyond 2026 [5] - The partner, Janssen Pharmaceuticals Inc., completed the Phase 2 study of ADX71149 for epilepsy, but the top-line results did not show statistical significance [5] Cash Position - Cash and cash equivalents decreased to CHF 1.6 million as of March 31, 2024, down from CHF 5.6 million a year earlier, a decrease of CHF 4 million [7] - The decrease in cash was primarily due to cash used in operating activities, partially offset by funds raised from an institutional investor in April 2023 [7]

Core Viewpoint - Addex Therapeutics is set to hold its 2024 Annual General Meeting on June 28, 2024, focusing on key corporate governance matters and financial approvals for the year 2023 [1] Group 1: Annual General Meeting Agenda - Approval of the Annual Report, Annual Financial Statements, and Consolidated Financial Statements for the business year 2023 [2] - Consultative vote on the Compensation Report for the business year 2023 [2] - Re-elections of members of the Board of Directors, including Vincent Lawton as Chairman [2][3] - Amendments to the Articles of Association, including an increase in the capital band and conditional share capital [2][3] Group 2: Company Overview - Addex Therapeutics is a clinical-stage biopharmaceutical company focused on developing novel small molecule allosteric modulators for neurological disorders [4] - The lead drug candidate, ADX71149, has completed a Phase 2 clinical study for epilepsy, while dipraglurant is under evaluation for dyskinesia associated with Parkinson's disease [4] - Addex has partnerships with Indivior for GABAB PAM programs and holds a 20% share in Neurosterix LLC, which is advancing multiple allosteric modulator programs [4]

Geneva, Switzerland, May 31, 2024 - Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for neurological disorders, announced today that it will issue its Q1 2024 Financial Results on June 6, 2024. Tim Dyer, CEO and Mikhail Kalinichev, Head of Translational Science, will provide a business update and a review of the Addex product pipeline during a teleconference and webcast for investors, analys ...

Core Points - Addex Therapeutics will release its Q1 2024 financial results on June 6, 2024, and will provide a business update and product pipeline review during a teleconference and webcast [1] - The teleconference will be held at 16:00 CEST (15:00 BST / 10:00 EDT / 07:00 PDT) on the same day [1] Company Overview - Addex Therapeutics is a clinical-stage biopharmaceutical company focused on developing novel small molecule allosteric modulators for neurological disorders [3] - The lead drug candidate, ADX71149, is a positive allosteric modulator (PAM) for mGlu2 and has completed a Phase 2 clinical study for epilepsy [3] - The second clinical program, dipraglurant, is a negative allosteric modulator (NAM) for mGlu5, under evaluation for dyskinesia associated with Parkinson's disease and post-stroke/TBI recovery [3] - Addex has a partnership with Indivior to advance multiple drug candidates for substance use disorder and is also developing a GABAB PAM program for chronic cough [3] - The company holds a 20% share in Neurosterix LLC, which is advancing several allosteric modulator programs for various neurological conditions [3] - Addex shares are listed on the SIX Swiss Exchange and NASDAQ under the ticker symbol "ADXN" [3]

Geneva, Switzerland, May 8, 2024 - Addex Therapeutics (NASDAQ:ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug development, announced today that CEO, Tim Dyer, will present at the Bio€quity Europe 2024 conference taking place May 12 - 14, 2024 at the Kursaal Congress Center in San Sebastián, Spain. In his in-person presentation, scheduled for 14:00 – 14:12 CEST, on Monday May 13, 2024 in Room 6 + 7, Mr. Dyer will provide a corporate update and discuss recent develop ...

Geneva, Switzerland, May 8, 2024 - Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug development, announced today that CEO, Tim Dyer, will present at the Bio€quity Europe 2024 conference taking place May 12 - 14, 2024 at the Kursaal Congress Center in San Sebastián, Spain. In his in-person presentation, scheduled for 14:00 – 14:12 CEST, on Monday May 13, 2024 in Room 6 + 7, Mr. Dyer will provide a corporate update and discuss recen ...

Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, April 29, 2024 - Addex Therapeutics (NASDAQ:ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for neurological disorders, today announced top-line data from a Phase 2 epilepsy study evaluating adjunctive ADX71149 (JNJ-40411813) administration in patients with focal onset seizures with suboptimal response to levetiracetam or brivaracetam. The Phase 2 study did not ac ...

Addex Therapeutics Ltd (NASDAQ:ADXN) Q4 2023 Earnings Conference Call April 18, 2024 10:00 AM ET Company Participants Tim Dyer - Chief Executive Officer Mikhail Kalinichev - Head, Translational Science Conference Call Participants Joanne Lee - Maxim Group Raghuram Selvaraju - H.C. Wainwright & Co. Michael Okunewitch - Maxim Group Operator Good day and thank you for standing by. Welcome to the Addex Therapeutics Full Year 2023 Financial Results and Corporate Update Conference Call. At this time, all particip ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 20-F (Mark One) ☐ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to OR ☐ SHELL COMPANY REPORT PURSUANT TO SECT ...

[Full Year 2023 Financial Results and Corporate Update](index=1&type=section&id=Addex%20Therapeutics%20Reports%20Full%20Year%202023%20Financial%20Results%20and%20Provides%20Corporate%20Update) Addex Therapeutics reported full-year 2023 financial results, emphasizing Neurosterix launch, operational milestones, and improved financial performance [Introduction and CEO Remarks](index=1&type=section&id=Introduction%20and%20CEO%20Remarks) Addex Therapeutics announced 2023 financial results, emphasizing the transformational Neurosterix launch and key upcoming milestones - The launch of Neurosterix, in collaboration with Perceptive Advisors, is considered a **transformational transaction** for Addex, validating decades of work[3](index=3&type=chunk) - Top-line data from the ADX71149 Phase 2 epilepsy study is anticipated by **mid-May 2024**[1](index=1&type=chunk)[3](index=3&type=chunk) - The company plans to start IND-enabling studies for drug candidates from its GABAB PAM collaboration with Indivior by the **end of 2024**[3](index=3&type=chunk) [Operating Highlights](index=1&type=section&id=Operating%20Highlights) Key operational milestones in 2023 include the Neurosterix launch, extended Indivior collaboration, and preclinical program advancements - Launched Neurosterix with Perceptive Advisors, securing **USD 63 million** to advance the allosteric modulator drug discovery platform and unpartnered preclinical portfolio[1](index=1&type=chunk)[4](index=4&type=chunk) - The GABAB PAM collaboration with Indivior for substance use disorders was extended to the **end of June 2024**, with an additional **CHF 2.7 million** in research funding[4](index=4&type=chunk) - An Addex-led consortium secured a **EUR 4 million** Eurostars grant for its mGlu2NAM mild neurocognitive disorders discovery program[4](index=4&type=chunk) - Data supporting the development of dipraglurant in post-stroke recovery was published in the journal *Brain*[4](index=4&type=chunk) [Financial Performance](index=1&type=section&id=Financial%20Performance) Addex significantly reduced 2023 operating and net losses, driven by decreased R&D and G&A expenses Key Financial Data (CHF in thousands) | Financial Metric | 2023 | 2022 | Change | | :--- | :--- | :--- | :--- | | Income | 1,647 | 1,445 | 202 | | R&D expenses | (6,962) | (14,665) | 7,703 | | G&A expenses | (4,966) | (7,300) | 2,334 | | Total operating loss | (10,281) | (20,520) | 10,239 | | Net loss for the period | (10,556) | (20,804) | 10,248 | | Basic and diluted net loss per share (CHF) | (0.14) | (0.46) | 0.32 | | Cash and cash equivalents | 3,865 | 6,957 | (3,092) | - R&D expenses decreased by **CHF 7.7 million** to **CHF 7.0 million** in 2023, mainly due to reduced external R&D activities related to dipraglurant[7](index=7&type=chunk) - G&A expenses fell by **CHF 2.3 million** to **CHF 5.0 million** in 2023, primarily due to lower share-based service costs and D&O insurance costs[7](index=7&type=chunk) - The net loss decreased by **CHF 10.2 million**, largely as a result of the reduction in R&D expenses[7](index=7&type=chunk) - Cash and cash equivalents decreased by **CHF 3.1 million**, reflecting cash used in operations, partially offset by proceeds from a **USD 5 million** equity offering in April 2023 and research funding from Indivior[7](index=7&type=chunk) [Corporate Information](index=2&type=section&id=Corporate%20Information) Addex Therapeutics, a clinical-stage biopharmaceutical company, provided corporate details and forward-looking statements - Addex is a clinical-stage biopharmaceutical company focused on developing novel small molecule allosteric modulators for neurological disorders[11](index=11&type=chunk) - The company's lead drug candidate is ADX71149 for epilepsy, followed by dipraglurant for Parkinson's-related dyskinesia and post-stroke recovery[11](index=11&type=chunk) - A conference call and webcast to review the financial results was scheduled for **April 18, 2024**, with registration details provided[9](index=9&type=chunk)[10](index=10&type=chunk) - The press release contains forward-looking statements, and actual results may differ materially due to various risks and uncertainties detailed in the company's SEC filings, including the Annual Report on Form 20-F[13](index=13&type=chunk)